United States-based provider of a range of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology sectors, Charles River Laboratories International, has acquired KWS BioTest, a United Kingdom-based contract research organisation that specialises in in vitro and in vivo discovery testing services for immuno-oncology, inflammation and allergy, autoimmune disease and antimicrobials, antivirals and vaccinology, it was reported on Friday.
The deal is valued at around GBP15m. It is intended to expand Charles River's present discovery expertise in the field of immunology. Charles River is also expected to offer its clients more tools in the therapeutic research areas of oncology and immunology.
KWS BioTest's services include both preclinical and clinical phases. The company has an expert team of cell biologists to support early drug research to support later stage drug development programs.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007